Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Quarterly Earnings Results, Beats Estimates By $0.24 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL) released its quarterly earnings results on Monday. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.24, FiscalAI reports.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL traded up $0.02 during trading on Monday, reaching $1.74. 1,273,694 shares of the stock traded hands, compared to its average volume of 1,531,419. The stock has a 50-day moving average of $2.74 and a two-hundred day moving average of $3.41. Zentalis Pharmaceuticals has a 52-week low of $1.25 and a 52-week high of $6.95. The stock has a market cap of $124.71 million, a P/E ratio of -0.89 and a beta of 1.91.

Insider Transactions at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, major shareholder Group Walters bought 4,335,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the purchase, the insider owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. This trade represents a 32.09% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on ZNTL shares. Wall Street Zen lowered Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Leerink Partners started coverage on shares of Zentalis Pharmaceuticals in a report on Monday, October 5th. They set an “outperform” rating and a $8.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Friday, October 2nd. Mizuho started coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 price target for the company. Finally, William Blair initiated coverage on shares of Zentalis Pharmaceuticals in a research note on Wednesday, September 16th. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Zentalis Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $7.50.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments.

Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.